CHOICE KERGUELEN 2 : Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands

NCT ID: NCT07275489

Last Updated: 2025-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

9 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-20

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Living for long periods in extreme environments-like Antarctic research stations or space missions-can have a significant impact on human health, especially on the immune system. Scientists have observed that people in such isolated conditions often experience more infections and a reactivation of viruses that usually stay dormant in the body, such as Herpes viruses. These changes affect both parts of the immune system: the rapid-response "innate" system and the slower, more specific "adaptive" system.

These immune disruptions may be caused by multiple stressors: ongoing psychological stress, disturbed sleep and light cycles (circadian rhythm disruption), and the challenges of living in confined, isolated, and extreme environments. While space missions and Antarctic overwintering programs have provided some insight into these issues, scientists still lack a detailed understanding of how the immune system adapts-or fails to adapt-over time in such conditions.

To help fill this gap, the CHOICE Kerguelen 2 study will follow a group of healthy young adults who will spend one year (from November 2025 to November 2026) in Port-aux-Français, a remote French research station on the Kerguelen Islands in the sub-Antarctic. These volunteers are participating in a civic service program and will be living in a highly isolated environment for the duration of their mission. The CHOICE Kerguelen study is conducted in collaboration with the French Polar Institute (IPEV).

The goal of the study is to collect and store a broad range of biological samples-including blood, saliva, stool, urine, and hair-from these volunteers at four time points during the time of their confinement on the Kerguelent Islands: tevery three months during their stay. These samples will be than analyzed to characterize the immune profiles and intestinal microbiota of the subjects assess eventual viral reactivations and stress biological markers. These analyses will allow to better understand how the immune system reacts to prolonged isolation, and to identify immune profiles that may develop under prolonged stress and limited social contact.

The long-term aim of this project is not only to improve our understanding of human immunity in extreme environments, but also to inform medical research for people living with chronic illness. By studying healthy individuals placed in physically and mentally challenging environments, scientists can better understand how stress and isolation may weaken immune defenses. The findings may one day help design new approaches to support immune health in vulnerable populations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Health in Extreme Conditions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HD (healthy donors)

blood ponction

Intervention Type OTHER

blood ponction

urines collection

Intervention Type OTHER

urines collection

hair collection

Intervention Type OTHER

hair collection

saliva collection

Intervention Type OTHER

saliva collection

stools collection

Intervention Type OTHER

stools collection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood ponction

blood ponction

Intervention Type OTHER

urines collection

urines collection

Intervention Type OTHER

hair collection

hair collection

Intervention Type OTHER

saliva collection

saliva collection

Intervention Type OTHER

stools collection

stools collection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy people aged \> 18 years
* Participant affiliated with or benefiting from a social security system
* Participant has signed informed consent
* Participant staying as an overwintering member at Kerguelen from November 2025 to November 2026
* Participant included in the CELREMED research project of the University Hospital of Angers on helathy volunteers in the context of CHOICE Kerguelen 1 protocol

Exclusion Criteria

* age \< 18 years
* Pregnant, breastfeeding, or postpartum woman
* immunocompromised people (primary immunodeficiency, HIV infection or immunosupressive treatment)
* Person refusing to participate in the study
* Person with a history of autoimmune disease - -Person deprived of liberty by judicial or administrative decision
* Person undergoing involuntary psychiatric treatment
* Person subject to a legal protection measure
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut Polaire Français Paul Emile Victor

UNKNOWN

Sponsor Role collaborator

University Hospital, Angers

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Charline MIOT, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Angers

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital SAMUKER, Port-aux-français/ Archipel KERGUELEN /Terres Australes et Antarctiques Françaises

Port-aux-Français, Terres Australes Et Antarctiques Françaises, French Southern and Antarctic Lands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

French Southern and Antarctic Lands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Charline MIOT, MD

Role: CONTACT

Phone: 02 41 35 36 37

Email: [email protected]

Anthéa LOIEZ

Role: CONTACT

Phone: 02 41 35 36 37

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marine MEYERBER, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-A02538-41

Identifier Type: OTHER

Identifier Source: secondary_id

49RC25_0439

Identifier Type: -

Identifier Source: org_study_id